Zelira Therapeutics (AU:ZLD) has released an update.
Zelira Therapeutics is gearing up to present its latest business advancements at the Automic Invest 2024 conference, highlighting its successful proprietary cannabinoid medications like HOPE® and ZENIVOL®. With a robust pipeline and strategic partnerships, Zelira is expanding its market presence in the US, Australia, and Germany, aiming for significant growth in the global cannabinoid-based medicine sector.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.